Do analysts rate THAR or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 536.65%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is THAR or ALLR more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Allarity Therapeutics N/A -109.94% -47.27%

Is ALLR or PEPG more profitable?

PepGen's return on equity of -59.89% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% PepGen N/A -59.89% -49.62%

Is ALLR or BMEA more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Biomea Fusion N/A -265.37% -103.96%

Allarity Therapeutics (ALLR) Competitors

$1.61 +0.03 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 -0.02 (-0.93%)

As of 07:54 PM Eastern

Compare

ALLR vs. THAR, PEPG, VRCA, CRDF, and BMEA

Should you buy Allarity Therapeutics stock or one of its competitors? MarketBeat compares Allarity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allarity Therapeutics include Tharimmune (THAR), PepGen (PEPG), Verrica Pharmaceuticals (VRCA), Cardiff Oncology (CRDF), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does Allarity Therapeutics compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 536.65%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tharimmune has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by insiders. Comparatively, 0.0% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Allarity Therapeutics has higher revenue and earnings than Tharimmune. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Allarity Therapeutics	$320K	80.05	-$11.23M	-$0.72	N/A

Allarity Therapeutics' return on equity of -109.94% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Allarity Therapeutics	N/A	-109.94%	-47.27%

In the previous week, Allarity Therapeutics had 3 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Allarity Therapeutics and 0 mentions for Tharimmune. Allarity Therapeutics' average media sentiment score of 0.72 beat Tharimmune's score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Allarity Therapeutics	Positive

Summary

Allarity Therapeutics beats Tharimmune on 11 of the 14 factors compared between the two stocks.

How does Allarity Therapeutics compare to PepGen?

Allarity Therapeutics (NASDAQ:ALLR) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Allarity Therapeutics has higher revenue and earnings than PepGen. Allarity Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	80.05	-$11.23M	-$0.72	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Allarity Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.72 beat PepGen's score of 0.63 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
PepGen	Positive

Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 536.65%. PepGen has a consensus target price of $11.60, suggesting a potential upside of 740.58%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

PepGen's return on equity of -59.89% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
PepGen	N/A	-59.89%	-49.62%

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

PepGen beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Allarity Therapeutics compare to Verrica Pharmaceuticals?

Allarity Therapeutics (NASDAQ:ALLR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Allarity Therapeutics has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	80.05	-$11.23M	-$0.72	N/A
Verrica Pharmaceuticals	$35.58M	2.96	-$17.89M	-$1.03	N/A

In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.72 beat Verrica Pharmaceuticals' score of 0.63 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
Verrica Pharmaceuticals	Positive

Allarity Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Allarity Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Allarity Therapeutics' return on equity of -109.94% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 0.0% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Allarity Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 536.65%. Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 136.93%. Given Allarity Therapeutics' higher possible upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Allarity Therapeutics beats Verrica Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Allarity Therapeutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Allarity Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Allarity Therapeutics	N/A	-109.94%	-47.27%

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by insiders. Comparatively, 0.0% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Allarity Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	177.30	-$45.85M	-$0.67	N/A
Allarity Therapeutics	$320K	80.05	-$11.23M	-$0.72	N/A

Cardiff Oncology has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

In the previous week, Cardiff Oncology had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.72 beat Cardiff Oncology's score of -0.12 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiff Oncology	Neutral
Allarity Therapeutics	Positive

Cardiff Oncology currently has a consensus price target of $8.75, suggesting a potential upside of 471.90%. Allarity Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 536.65%. Given Allarity Therapeutics' higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cardiff Oncology beats Allarity Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Allarity Therapeutics compare to Biomea Fusion?

Allarity Therapeutics (NASDAQ:ALLR) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Allarity Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 0.0% of Allarity Therapeutics shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Allarity Therapeutics has higher revenue and earnings than Biomea Fusion. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	80.05	-$11.23M	-$0.72	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Allarity Therapeutics' return on equity of -109.94% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Biomea Fusion	N/A	-265.37%	-103.96%

Allarity Therapeutics currently has a consensus price target of $10.25, indicating a potential upside of 536.65%. Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 648.90%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Biomea Fusion had 2 more articles in the media than Allarity Therapeutics. MarketBeat recorded 5 mentions for Biomea Fusion and 3 mentions for Allarity Therapeutics. Biomea Fusion's average media sentiment score of 0.78 beat Allarity Therapeutics' score of 0.72 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
Biomea Fusion	Positive

Summary

Biomea Fusion beats Allarity Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Allarity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLR vs. The Competition

Export

Metric	Allarity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.14M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-2.24	18.68	24.75	23.76
Price / Sales	80.05	297.55	508.64	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	2.64	8.06	10.47	6.72
Net Income	-$11.23M	$23.83M	$3.56B	$337.35M
7 Day Performance	-4.73%	-2.82%	-1.11%	-2.54%
1 Month Performance	3.87%	2.22%	1.28%	1.42%
1 Year Performance	82.68%	37.70%	21.20%	24.71%

Allarity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLR Allarity Therapeutics	2.5885 of 5 stars	$1.61 +1.9%	$10.25 +536.6%	+86.7%	$25.14M	$320K	N/A	10	Analyst Forecast Short Interest Decrease
THAR Tharimmune	N/A	$2.81 -9.5%	N/A	+52.3%	$105.83M	N/A	N/A	2	Gap Up
PEPG PepGen	2.7834 of 5 stars	$1.45 -1.4%	$11.60 +700.0%	-10.0%	$101.68M	N/A	N/A	30	Analyst Upgrade
VRCA Verrica Pharmaceuticals	3.1158 of 5 stars	$5.79 -1.9%	$14.50 +150.4%	-2.1%	$101.36M	$35.58M	N/A	40
CRDF Cardiff Oncology	1.7183 of 5 stars	$1.51 +2.0%	$10.10 +568.9%	-61.3%	$101.19M	$590K	N/A	20	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLR) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allarity Therapeutics (ALLR) Competitors

ALLR vs. THAR, PEPG, VRCA, CRDF, and BMEA

How does Allarity Therapeutics compare to Tharimmune?

Summary

How does Allarity Therapeutics compare to PepGen?

Summary

How does Allarity Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Allarity Therapeutics compare to Cardiff Oncology?

Summary

How does Allarity Therapeutics compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allarity Therapeutics (ALLR) Competitors

ALLR vs. THAR, PEPG, VRCA, CRDF, and BMEA

How does Allarity Therapeutics compare to Tharimmune?

Do analysts rate THAR or ALLR?

Which has more volatility and risk, THAR or ALLR?

Do insiders & institutionals have more ownership in THAR or ALLR?

Which has better earnings & valuation, THAR or ALLR?

Is THAR or ALLR more profitable?

Does the media favor THAR or ALLR?

Summary

How does Allarity Therapeutics compare to PepGen?

Which has better earnings & valuation, ALLR or PEPG?

Which has more risk & volatility, ALLR or PEPG?

Does the media refer more to ALLR or PEPG?

Do analysts prefer ALLR or PEPG?

Is ALLR or PEPG more profitable?

Do institutionals & insiders hold more shares of ALLR or PEPG?

Summary

How does Allarity Therapeutics compare to Verrica Pharmaceuticals?

Which has higher earnings and valuation, ALLR or VRCA?

Does the media refer more to ALLR or VRCA?

Which has more volatility & risk, ALLR or VRCA?

Is ALLR or VRCA more profitable?

Do institutionals and insiders have more ownership in ALLR or VRCA?

Do analysts rate ALLR or VRCA?

Summary

How does Allarity Therapeutics compare to Cardiff Oncology?

Is CRDF or ALLR more profitable?

Do insiders & institutionals hold more shares of CRDF or ALLR?

Which has better valuation and earnings, CRDF or ALLR?

Which has more volatility & risk, CRDF or ALLR?

Does the media favor CRDF or ALLR?

Do analysts recommend CRDF or ALLR?

Summary

How does Allarity Therapeutics compare to Biomea Fusion?

Which has more risk & volatility, ALLR or BMEA?

Do institutionals & insiders believe in ALLR or BMEA?

Which has higher earnings and valuation, ALLR or BMEA?

Is ALLR or BMEA more profitable?

Do analysts prefer ALLR or BMEA?

Does the media refer more to ALLR or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools